446 related articles for article (PubMed ID: 27188329)
1. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.
Hwang YG; Balasubramani GK; Metes ID; Levesque MC; Bridges SL; Moreland LW
Arthritis Res Ther; 2016 May; 18(1):108. PubMed ID: 27188329
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
3. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
4. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
5. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
[TBL] [Abstract][Full Text] [Related]
6. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
7. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
[TBL] [Abstract][Full Text] [Related]
8. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
9. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
Al-Gareeb AIA; Gorial FI; Mahmood AS
Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
[TBL] [Abstract][Full Text] [Related]
11. Ferritin correlates with C-reactive protein and acute phase serum amyloid A in synovial fluid, but not in serum.
Kumon Y; Suehiro T; Nishiya K; Hashimoto K; Nakatani K; Sipe JD
Amyloid; 1999 Jun; 6(2):130-5. PubMed ID: 10439120
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid A in the assessment of early inflammatory arthritis.
Cunnane G; Grehan S; Geoghegan S; McCormack C; Shields D; Whitehead AS; Bresnihan B; Fitzgerald O
J Rheumatol; 2000 Jan; 27(1):58-63. PubMed ID: 10648018
[TBL] [Abstract][Full Text] [Related]
13. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis.
Shen C; Sun XG; Liu N; Mu Y; Hong CC; Wei W; Zheng F
Mol Med Rep; 2015 Feb; 11(2):1528-34. PubMed ID: 25352049
[TBL] [Abstract][Full Text] [Related]
14. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
Emery P; Horton S; Dumitru RB; Naraghi K; van der Heijde D; Wakefield RJ; Hensor EMA; Buch MH
Ann Rheum Dis; 2020 Apr; 79(4):464-471. PubMed ID: 31996367
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction.
Liu D; Yan J; Yun M; Yang M; Luo Y; Zhang J; Guo M; Yang M; Yuan W; Zou W; Li H; Hu Y
J Tradit Chin Med; 2016 Oct; 36(5):625-33. PubMed ID: 29933531
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
Shi ZC; Fei HP; Wang ZL
Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
[TBL] [Abstract][Full Text] [Related]
17. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
[TBL] [Abstract][Full Text] [Related]
18. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
19. Zymographic analysis using gelatin-coated film of the effect of etanercept on the extracellular matrix-degrading activity in synovial fluids of rheumatoid arthritis patients.
Kamataki A; Ishida M; Komagamine M; Yoshida M; Ando T; Sawai T
Int J Rheum Dis; 2016 Apr; 19(4):385-91. PubMed ID: 24618272
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
Patro PS; Singh A; Misra R; Aggarwal A
J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
